AstraZeneca to Discuss $400 Billion Merger with Bristol Myers Squibb

AstraZeneca is in talks with Bristol Myers Squibb regarding a possible merger valued at approximately $400 billion, according to the Financial Times. This potential deal could lead to one of the largest mergers in history within the pharmaceutical industry. Bristol Myers Squibb has had a proactive acquisition strategy, having bought seven companies since October 2007. The outcome of these discussions is still uncertain, but the combined company would have a significant presence in cancer treatment, impacting market dynamics for healthcare investors.